NVCR - ノボキュア （NovoCure Limited）

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure announced today that it will report financial results for the first quarter 2023 on May 4, 2023, before the U.S. financial markets open.

NovoCure has seen strong growth over the past decade but unable to post profits with large sums invested into the pipeline. Read why NVCR stock is a Buy.

NovoCure focuses on promoting Optune and Optune Lua, utilizing TTFields technology to target and destroy cancer cells. See why we recommend a buy on NVCR stock.

https://www.investing.com/news/pro/jpmorgan-downgrades-novocure-ltd-to-underweight-432SI-3033169

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure today announced the 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program.

Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor conferences. William Doyle, Executive Chairman, and Ashley Cordova, Chief Financial Officer, will participate in the 2022 Wells Fargo Healthcare Conference on September 7, 2022. Mr. Doyle and Ms. Cordova will take part in a fireside chat at 4:20 p.m. EDT, as well as one-on-one meetings with investors

Motley Fool contributor Brian Orelli shares why he loves this stock

NovoCure (NASDAQ: NVCR ) brought in sales totaling $140.87 million during Q2 according to data provided by Benzinga Pro . However, earnings decreased 416.63%, resulting in a loss of $24.01 million. In Q1, NovoCure brought in $137.55 million in sales but lost $4.65 million in earnings. Why Is ROCE Significant? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and … Full story available on Benzinga.com

NovoCure printed another successful quarter, but came in behind consensus below the bottom line. See why we are bullish on NVCR stock for long-term.

https://www.investing.com/news/pro/novocure-ltd-pt-lowered-to-105-at-truist-securities-432SI-2858107

In last trading session, NovoCure Limited (NASDAQ:NVCR) saw 0.65 million shares changing hands with its beta currently measuring 0.85. Company’s recent per share price level of $76.58 trading at -$0.6 or -0.78% at ring of the bell on the day assigns it a market valuation of $8.58B. That closing price of NVCR’s stock is at … NovoCure Limited (NASDAQ:NVCR) Is 22.21% Above Its 52-Week Low, But How Long Can It Continue? Read More »

NVCR earnings call for the period ending March 31, 2022.

NovoCure Limited (NASDAQ:NASDAQ:NVCR) Q1 2022 Earnings Conference Call April 28, 2022 8:00 AM ET Company Participants Ingrid Goldberg – Investor Relations Bill Doyle – Executive Chairman…

NovoCure (NASDAQ: NVCR ) reported its Q1 earnings results on Thursday, April 28, 2022 at 06:00 AM. Here''s what investors need to know about the announcement. Earnings NovoCure beat estimated earnings by 77.78%, reporting an EPS of $-0.04 versus an … Full story available on Benzinga.com

NovoCure press release (NVCR): Q1 GAAP EPS of -$0.04 beats by $0.15.Revenue of $137.55M (+2.1% Y/Y) beats by $3.26M.Gross margin for the quarter was 80%. As of March 31, 2022,…